文献

Background Information:

A histone deacetylase (HDAC) inhibitor currently in clinical trial.

Reference:

1. Mackay HJ, Hirte H, Colgan T, Covens A, Macalpine K, Grenci P, Wang L, Mason J, Pham PA, Tsao MS, Pan J, Zwiebel J, Oza AM. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010 Mar 19. [Epub ahead of print].
2. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O’Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010 Jan 15; 16(2):554-65.

APIM050320: BELINOSTAT

CAS No.: 414864-00-9.
Molecular Formula: C15H14N2O4S.
Molecular Weight: 318.4.
Purity: 99% (HPLC).
QC: LC/MS, 1HNMR.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.